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Abstract 
 
The emergence of multidrug resistant bacterial infections is a serious problem. Treatment options are limited to 
patients those are infected with multidrug resistant bacteria. We are in a desperate need of new antibiotics. 
Antisense oligomers of PNA (Peptide Nucleic Acid) were introduced in late 90’s as antibacterial agents in an 
intention to create a new class of bacterial specific antibiotic. Followed by several studies have demonstrated that 
antibacterial PNA oligomers are effective in a verity of pathogenic bacterial strains. Development of PNA-based 
drugs (PNA antibiotics) will help us to combat infections of drug resistant bacterial strains. 
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The number of multidrug resistant bacteria is 
increasing at an alarming rate. This is happening 
mainly due to the uncontrolled use of antibiotics and 
transfer of resistance genes within bacteria. The 
majority of previously discovered antibiotics are now 
not useful in eradicating multidrug resistant bacterial 
infections, although, in some cases, the combination 
of antibiotics still work. There are very few antibiotics 
such as ceftobiprole, linezolid, daptomycin, amikacin, 
etc. that are effective on multidrug resistant bacterial 
strains.  
 
The number of deaths associated with multidrug 
resistant bacterial infections is increasing everywhere 
in the world, indicating that we are not too far to 
reach the post-antibiotic era. Since the discovery of 
penicillin, not many new classes of antibiotic were 
discovered (Lewis, 2013); although, in recent years, 
the initiatives of discovering new antibacterial drugs 
have increased steadily. The need of new kinds of 
antibiotic is paramount.  
 
PNA oligomers were first introduced as antisense 
antibacterial agents in late 90’s (Good and Nielsen,  
1998). A few years later, it was shown that peptide 
conjugated PNA oligomers (antibacterial PNA) are 
capable of killing bacteria by inhibiting the function 
of acpP gene and provide protection from E. coli 
infection (Good et al, 2001). Thereafter, several 
studies have demonstrated the potential of 
antibacterial PNAs in inhibiting the growth of many 
human pathogenic bacteria (Ghosal, in press; Ghosal, 
2012). Further, it was shown that antibacterial PNAs 
are capable of reducing bacterial load in infection 
mice models (Tan et al, 2005; Bai et al, 2012). 
Antibacterial PNAs also inhibit the growth of 
Pseudomonas aeruginosa (Ghosal and Nielsen, 
2012), and anti-acpPPNAs are effective in inhibiting 
the growth of different strains of Pseudomonas 
aeruginosa. Furthermore, Pseudomonas aeruginosa 
LESB58 strain (a clinical isolate) showed sensitivity 
to lower doses of antibacterial PNAs compared to 
antibiotic ofloxacin and ceftazidime. A just-published 
study, which characterizes a Pseudomonas specific 
antibacterial PNA, highlighted that antibacterial PNA 
is capable of reducing the production of pro-
inflammatory cytokines in an in vitro cell culture 
infection model (Montagner et al, 2017). 
 
The potency of antibacterial PNA molecules depends 
on the properties of conjugated peptide and the PNA 
oligomer. The conjugated peptide helps in 
transportation of PNA oligomer into the bacterial 
cytosol; inside the bacterial cytosol, antisense PNA 
oligomer binds to the target RNA. In some cases, 
conjugated peptides degrade in bacterial periplasm 
after crossing the outer membrane (Gram-negative 
bacteria), and from periplasm, PNA oligomers 
transport to cytoplasm by inner membrane 
transporters, while some peptides remain attached to 
the PNA oligomers after crossing the bacterial 
membrane (Ghosal et al, 2013).        
 
Properties of antibacterial PNAs provide an 
advantage to design bacterial specific antibiotics. 
Designing of bacterial specific antibiotics is always 
advantageous as it lives other beneficial bacteria 
unharmed.  
 
The human body is colonized by a vast number of 
microorganisms where majority of them are 
represented by bacteria (Bäckhed et al, 2005). 
Recently, it has shown that bacteria secrete RNA, and 
these secreted RNA have the potential to alter the 
behavior of host cells (Ghosal et al, 2015; Fritz et al, 
2016; Koeppen et al, 2016). It would be relatively easy 
to design PNA-based inhibitors against those effector 
RNA molecules.  
 
Despite several advantages, delivery of antibacterial 
PNA oligomers is still a challenge; it requires a vehicle 
to get into the bacterial cell. Several studies need to be 
done to take antibacterial PNAs to the clinics. 
Further, instead of using antibacterial PNA alone as 
an antibiotic, it would also be advantageous to use 
antibacterial PNA in combination with commonly 
used drugs where antibacterial PNA will be used to 
sensitize multidrug resistant bacteria to the drugs.    
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